Everyone wants to be accepted and feel like they belong. These are innately human traits, and they don’t go away when we leave the grade school playground, high school cafeteria or university quad. We want to feel safe and accepted at work, too, and that feeling is important to professional success and effectiveness. From a…
The ACR Releases an Updated Treatment Guideline for Rheumatoid Arthritis
In early June, the ACR released an updated guideline on the management of rheumatoid arthritis, which includes new recommendations for specific high-risk groups.1 The guideline includes 44 recommendations—seven of which are strong and 37 conditional. It underscores the role of methotrexate as a cornerstone therapy and emphasizes minimizing glucocorticoids, when possible. Guideline Development Process At…
Racism As a Public Health Crisis
On March 29, Brandon Elliot walked up to a 65-year-old Filipino American woman near Times Square and kicked her in the chest. Footage from the security camera of a nearby luxury apartment building recorded the attack: Elliot shoved her to the ground, and then repeatedly kicked and stomped on her, while shouting, “You don’t belong…
A Unified Advocacy Voice for Rheumatology
One thing that became clear very quickly this past year was that the COVID-19 pandemic would change the way we deliver care to patients. What has not changed amid an evolving healthcare landscape is our driving focus to ensure our patients’ access to rheumatology care and the availability of state-of-the-art treatments. We know you share…
ACR Advocacy: 2021 Midyear Update
Beginning in the late 1800s, Eliza Ruhamah Scidmore, U.S. diplomat and writer, spent 24 years advocating for sakura, or Japanese cherry trees, to be planted in Washington, D.C. After unsuccessfully petitioning every U.S. Army Superintendent of Public Buildings and Grounds for over two decades, she wrote a letter to First Lady Helen Herron Taft about…
RheumPAC Donors Discuss Healthcare Legislation, Drug Pricing with Rep. Lloyd Doggett
At a virtual event with the chair of the Ways & Means Subcommittee on Health, RheumPAC donors were able to share concerns and recommendations about drug pricing policies and how they affect providers and patients.
How Immunosuppression May Affect COVID-19 Vaccine Response
Although we can expect to learn much more, preliminary data are now available on the potential safety and effectiveness of COVID-19 vaccines in rheumatology patients. The picture is likely to be nuanced, with not all types of immunosuppressive treatments having identical impacts on vaccine response. Rheumatologists should use caution in interpreting early reports, while continuing…
ACR Quality of Care Committee Impresses with Its Recent Productivity
Over the past 18 months, the ACR’s Quality of Care (QOC) Committee has helped produce an impressive number of resources that will help rheumatologists deliver the best possible care. Working through specific projects supervised under its Criteria, Guideline, Guidance, and Quality Measure subcommittees, the QOC Committee has developed new sets of disease criteria, clinical guidelines,…
10 Tips to Master E/M Coding Changes
Learn to properly use the revised CPT codes to document your time and medical decision making during patient visits to help ensure your practice is appropriately remunerated.
Rheumatology Care: Access & Affordability
Presenters at the Access in Rheumatology meeting held in advance of the ACR’s State-of-the-Art Clinical Symposium took a deep dive into the access challenges faced by rheumatology patients and discussed possible solutions. Treatment At least until 2026, prescription drug spending will exceed the U.S. gross domestic product (GDP) and health spending, said rheumatologist Colin C….
Case Report: Digital Ulcers & Weight Loss in a Pediatric Patient
Juvenile dermatomyositis (JDM) is a childhood form of inflammatory myopathy affecting children younger than 18 years. The diagnosis of JDM is based on characteristic clinical features of proximal muscle weakness, skin rash, elevated muscle enzymes, magnetic resonance imaging and muscle biopsy.1 Autoantibodies seen in patients with inflammatory myopathy are not only associated with particular phenotypes…
Case Report: Saddle Nose Deformity in IgG4-Related Disease
Immunoglobulin G4-related disease (IgG4-related disease) is relatively rare, although with greater recognition it is becoming more frequently diagnosed. Some of the more common presentations of the disease include aortitis, cholangitis, autoimmune pancreatitis, sclerosing sialadenitis, orbital disease with proptosis and subacute mass development in the affected organ.1 It has protean manifestations and is diagnosed by classic…
Studies Probe Treating Rheumatoid Arthritis with Vagus Nerve Stimulation
When rheumatologists think about rheumatoid arthritis (RA), they are apt to picture the synovium, contemplate such antibodies as rheumatoid factor and those to citrullinated proteins, and consider how this interplay of factors manifests in disease. What is not as commonly discussed is the role the autonomic nervous system plays in the pathogenesis and symptomatology of…
Case Report: Does a Young Woman with Gitelman Syndrome Have Gout?
Gout is the most common type of inflammatory arthritis in adults, and it typically occurs in men over the age of 50. When gout presents in younger patients or in women, this should warrant consideration of secondary causes. We describe an unusual genetic cause of tophaceous gout in a young, premenopausal woman. Case Report In…
Artificial Intelligence Gives Rheumatologists an Assist
As the novel coronavirus that causes COVID-19 spreads across the globe, innovative thinking is needed more than ever to counter the devastating effects on the physical and socioeconomic health of individuals and communities. Innovations in healthcare delivery not yet fully realized prior to the pandemic, such as the adoption of telehealth, are moving to the…
Channel Policy Frustrations into Advocacy to Improve Patient Care
Frustrated with policies he viewed as obstacles to optimal patient care, Howard Yang, MD, RhMSUS, tried advocacy as a way to turn those feelings into positive action—an eye-opening and rewarding experience he strongly recommends.
Case Report: Child Develops Coronary Artery Aneurysms with GPA
In September 2019, a previously healthy, 9-year-old white girl presented to the emergency department following two months of sinusitis and unexplained fever responsive to ibuprofen. She presented with anorexia; a 9 lb. weight loss; intermittent, nonbilious, nonbloody emesis; and occasional epistaxis with digital manipulation of the nose. Six weeks prior to admission, she had presented to…
Gut Feeling: A Comprehensive Look at the Pathogenesis, Management & Treatment of Inflammatory Bowel Disease
Patients with autoimmune diseases, such as spondyloarthritis, are at risk of developing inflammatory bowel disease. Here are considerations for its management and treatment.
Sarcoidosis in the Spotlight: Screening, Treatment & More Insights into Sarcoidosis
An expert discussed the screening and treatment of sarcoidosis and drug-induced sarcoidosis-like reactions during the 2021 ACR State-of-the-Art Clinical Symposium.
Myositis Management: Clinical Trials Provide New Insights into Treatment Options
Advancements in the treatment of myositis are on their way, according to Hector Chenoy, PhD, FRCP, who outlined the latest clinical trials during the 2021 ACR State-of-the-Art Clinical Symposium.
Rheum After 5: Dr. Eric Schned Shares Memories of Woodstock
When Eric S. Schned, MD, was 19 years old, he spotted a tiny ad in his local newspaper for a concert. As days and weeks passed, the ad grew bigger as bands were added to the lineup. He, his twin brother and two friends decided the concert “looked really cool” and purchased tickets. That may…
Pegloticase Safe & Effective for Patients with Gout on Dialysis
Pegloticase is safe and effective to treat patients with refractory gout who are undergoing dialysis, according to recently presented research.
The Race Is On: Clinical Trials Begin for Agents Biosimilar to Denosumab
As the U.S. and other patents for branded denosumab products get closer to expiring, drug manufacturers are initiating clinical trials for more affordable, biosimilar versions of the treatment.